Path Less Traveled: Targeting Rare Driver Oncogenes in Non–Small-Cell Lung Cancer

Sun Min Lim, Jii Bum Lee, Yuko Oya, Jorn Nutzinger, Ross Soo

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


Over the past decade, tremendous efforts have been made in the development of targeted agents in non–small-cell lung cancer (NSCLC) with nonsquamous histology. Pivotal studies have used next-generation sequencing to select the patient population harboring oncogenic driver alterations that are targetable with targeted therapies. As treatment paradigm rapidly evolves for patients with rare oncogene-driven NSCLC, updated comprehensive overview of diagnostic approach and treatment options is paramount in clinical settings. In this review article, we discuss the epidemiology, molecular testing, and landmark clinical trials addressing the targeted agents for ROS1 rearrangement, METex14 skipping mutation, EGFR exon 20 insertion, KRAS G12C mutation, HER2 mutation, RET fusion, NTRK fusion, and BRAF mutations.

Original languageEnglish
Pages (from-to)47-56
Number of pages10
JournalJCO Oncology Practice
Issue number1
Publication statusPublished - 01-01-2024

All Science Journal Classification (ASJC) codes

  • Oncology
  • Health Policy
  • Oncology(nursing)


Dive into the research topics of 'Path Less Traveled: Targeting Rare Driver Oncogenes in Non–Small-Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this